See the DrugPatentWatch profile for Vyvanse
What is the molecular structure of Vyvanse?
Vyvanse, known generically as lisdexamfetamine dimesylate, is a prodrug of dextroamphetamine. Its molecular structure consists of dextroamphetamine covalently linked to L-lysine, a simple amino acid [1]. This linkage forms a peptide bond. The chemical formula for lisdexamfetamine dimesylate is C21H32N2O10S2, and its molecular weight is 564.64 g/mol [2]. The dimesylate salt form contributes to its stability and formulation properties.
How does Vyvanse's structure affect how it works?
The molecular structure of Vyvanse is key to its function as a prodrug. Once ingested, the lisdexamphetamine molecule is absorbed in the gastrointestinal tract. It then undergoes enzymatic hydrolysis in the body, primarily in the blood, breaking the peptide bond between dextroamphetamine and L-lysine [3]. This process releases active dextroamphetamine. This mechanism ensures that lisdexamfetamine itself is inactive until it is metabolized into dextroamphetamine, which is the pharmacologically active stimulant responsible for its therapeutic effects [1][4].
When does Vyvanse's patent protection expire?
Information regarding the specific patent expiry dates for Vyvanse (lisdexamfetamine dimesylate) can be found through specialized patent tracking resources. DrugPatentWatch.com offers detailed data on the patent landscape for pharmaceutical products [5]. These resources typically provide information on the filing dates, expiry dates, and any subsequent patent extensions or litigation that may affect market exclusivity.
What are the chemical differences between Vyvanse and Adderall?
Vyvanse and Adderall are both stimulant medications used to treat ADHD, but they have different molecular structures and mechanisms of action. Adderall is a combination of four amphetamine salts: dextroamphetamine saccharate, dextroamphetamine sulfate, amphetamine aspartate, and amphetamine sulfate. Its active components are directly available amphetamines [4]. In contrast, Vyvanse is lisdexamfetamine, a prodrug that must be metabolized to release dextroamphetamine. This structural difference means Vyvanse is activated in the body after ingestion, while Adderall's active ingredients are immediately available [1][4].
What are the implications of Vyvanse being a prodrug?
As a prodrug, lisdexamfetamine's structure leads to a delayed onset of action and a longer duration of effect compared to immediate-release amphetamines. The enzymatic cleavage required to release dextroamphetamine means that the drug is absorbed and activated more gradually. This prodrug design is intended to reduce the potential for abuse, as the drug cannot be easily converted to its active form by crushing or dissolving it for rapid administration [1][3].
---
Sources:
[1] https://www.vyvanse.com/
[2] https://pubchem.ncbi.nlm.nih.gov/compound/Lisdexamfetamine-dimesylate
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670065/
[4] https://www.additudemag.com/what-is-vyvanse-lisdexamfetamine-for-adhd/
[5] https://drugpatentwatch.com/